Ocular Surface最新文献_第2页

The clinical outcomes of minor salivary gland transplantation for severe dry eye disease secondary to chronic Stevens-Johnson syndrome 小唾液腺移植治疗慢性史蒂文斯-约翰逊综合征继发性严重干眼症的临床疗效。

IF 5.9 1区医学

Ocular Surface Pub Date : 2024-08-14 DOI: 10.1016/j.jtos.2024.08.010

{"title":"The clinical outcomes of minor salivary gland transplantation for severe dry eye disease secondary to chronic Stevens-Johnson syndrome","authors":"","doi":"10.1016/j.jtos.2024.08.010","DOIUrl":"10.1016/j.jtos.2024.08.010","url":null,"abstract":"<div><h3>Purpose</h3><p>To study the outcomes of minor salivary gland transplantation for severe dry eye disease secondary to chronic Steven Johnson Syndrome.</p></div><div><h3>Methods</h3><p>It was an ambispective, interventional case series conducted at Rajendra Prasad Centre for Ophthalmic Sciences, Delhi, India from 2022 to 2023 evaluating the outcomes of minor salivary gland transplantation with anchorage of the minor salivary glands to superior rectus muscle in twenty cases of severe dry eye disease secondary to chronic Steven-Johnson Syndrome. The pre-operative clinical parameters were compared to those at post-operative 1 year follow-up.</p></div><div><h3>Results</h3><p>At 1 year follow-up, there was an improvement in mean Schirmer-1 value (p = 0.0004), hyperemia score (p = 0.0004), keratinization score (p = 0.04), corneal epithelial defect score (p = 0.0004), corneal opacification score (p = 0.001), corneal neovascularization score (p = 0.001), palisades of Vogt score (p = 0.007), corneal keratinization score (p = 0.04) and corneal conjunctivalization score (p = 0.08).</p></div><div><h3>Conclusion</h3><p>The minor salivary gland transplantation is a viable management option for cases with severe dry eye disease secondary to chronic Steven Johnson Syndrome with clinical improvement in corneal and conjunctival parameters of the ocular surface.</p></div>","PeriodicalId":54691,"journal":{"name":"Ocular Surface","volume":null,"pages":null},"PeriodicalIF":5.9,"publicationDate":"2024-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141918473","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Punctal cautery in dry eye disease: A systematic review 干眼症的眼球穿孔烧灼术：系统回顾。

IF 5.9 1区医学

Ocular Surface Pub Date : 2024-08-09 DOI: 10.1016/j.jtos.2024.08.006

{"title":"Punctal cautery in dry eye disease: A systematic review","authors":"","doi":"10.1016/j.jtos.2024.08.006","DOIUrl":"10.1016/j.jtos.2024.08.006","url":null,"abstract":"<div><h3>Purpose</h3><p>To critically appraise the evidence on the efficacy and recanalization rates of permanent punctal occlusion via thermal or surgical means in managing dry eye disease (DED).</p></div><div><h3>Methods</h3><p>In PubMed, Scopus, and Cochrane databases, two authors systematically reviewed the literature for prospective studies on punctal cautery or surgical occlusion (excluding punctal plugs) for DED. The studied outcomes were changes in tear volume, tear film stability, punctal recanalization rates, and patient symptomatology.</p></div><div><h3>Results</h3><p>Nine studies (all single-arm) had 150 subjects (96 females). Five studies were on thermal punctal cauterization, and four used surgical occlusion techniques. One hundred eighty puncta were operated for eyes not responding to maximal lubricants or recurrent plug extrusion. DED etiologies were Sjogren's syndrome (78), cicatricial ADDE (27), graft-versus-host disease (12), and non-SS DED (50). Follow-up ranged from 3 to 24 months. At the final follow-up, improvements in Schirmer I and TBUT were 2.5 mm and 0.8s with thermal and 2.1 mm and 0.6s with surgical methods, respectively (P = 0.17 for Schirmer, P = 0.18 for TBUT). Punctal recanalization rates varied between thermal (0–38.7 %) and surgical (5–9%) techniques (p = 0.22). Different cautery devices show different recanalization rates; disposable thermal cautery tips directly inserted into the punctum had lesser recanalization than radiofrequency monopolar cautery. Most patients reported subjective improvement following the procedure, but no quantification measure was given in the studies. None of the published studies had a comparison group for performing a meta-analysis.</p></div><div><h3>Conclusion</h3><p>Based on non-comparative studies, thermal or surgical punctal occlusion improves tear volume in DED with similar recanalization rates; however, randomized controlled trials are needed to ascertain the real effects of punctal cautery on DED.</p></div>","PeriodicalId":54691,"journal":{"name":"Ocular Surface","volume":null,"pages":null},"PeriodicalIF":5.9,"publicationDate":"2024-08-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1542012424000879/pdfft?md5=b5fce60ef7482cd63e0f7b8b891c36aa&pid=1-s2.0-S1542012424000879-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141914996","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pipeline: Wiley Chambers, MD, FDA Ophthalmology regulator 管道：Wiley Chambers, MD, FDA 眼科监管者。

IF 5.9 1区医学

Ocular Surface Pub Date : 2024-08-08 DOI: 10.1016/j.jtos.2024.08.004

引用次数: 0

Duloxetine enhances PAX6 expression and suppresses innate immune responses in murine LPS-induced corneal inflammation 度洛西汀能增强 PAX6 的表达，并抑制 LPS 诱导的小鼠角膜炎症中的先天性免疫反应。

IF 5.9 1区医学

Ocular Surface Pub Date : 2024-08-08 DOI: 10.1016/j.jtos.2024.08.008

{"title":"Duloxetine enhances PAX6 expression and suppresses innate immune responses in murine LPS-induced corneal inflammation","authors":"","doi":"10.1016/j.jtos.2024.08.008","DOIUrl":"10.1016/j.jtos.2024.08.008","url":null,"abstract":"<div><h3>Background-aim</h3><p><em>PAX6</em> is a key regulator of eye development and epithelial homeostasis in the cornea. When deficient, chronic corneal inflammation, neovascularization and limbal stem cell deficiency can occur. Here we investigated the potential of duloxetine, a generic serotonin reuptake inhibitor that can upregulate PAX6 <em>in vitro</em>, for its <em>in vivo</em> activity in the context of corneal inflammation.</p></div><div><h3>Methods</h3><p>Duloxetine tolerance was tested in a human limbal stem cell line and isogenic CRISPR-knockout <em>PAX6</em><sup>+/−</sup> cells. C57BL/6-Wildtype mice were administered duloxetine eye drops at concentrations of 1 μM - 2 mM and tested for toxicity and corneal PAX6 expression. In LPS-induced corneal inflammation in mice, duloxetine's effect on PAX6 expression, corneal opacification and inflammatory responses were evaluated by <em>in vivo</em> corneal imaging, immunostaining, and whole-transcriptome microarray analysis.</p></div><div><h3>Results</h3><p>No toxicity was observed <em>in vitro</em> for duloxetine concentrations up to 10μΜ. <em>In vivo</em>, duloxetine drops were well-tolerated up to 50 μM. Duloxetine drops at 10μΜ significantly upregulated PAX6 protein levels in the cornea by 30 % within 2 days. In the LPS model, duloxetine resulted in a sustained 33 % PAX6 protein upregulation in the cornea at 7 days, and in reduced opacity within 2 days, accompanied by a significant dampening of IL-17A signaling, neutrophil degranulation, microglial activation, macrophage markers, and <em>MMP</em> expression, despite non-significant changes in total inflammatory cell infiltration.</p></div><div><h3>Conclusion</h3><p>Short-term administration of a repurposed generic drug, duloxetine, upregulates PAX6 protein levels in the cornea of mice and exerts an anti-inflammatory activity by dampening innate immune responses.</p></div>","PeriodicalId":54691,"journal":{"name":"Ocular Surface","volume":null,"pages":null},"PeriodicalIF":5.9,"publicationDate":"2024-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1542012424000867/pdfft?md5=6678d99b0a1e71244ed995c1d9482a7c&pid=1-s2.0-S1542012424000867-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141914994","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The effects of age and dysfunction on meibomian gland population dynamics 年龄和功能障碍对睑板腺数量动态的影响。

IF 5.9 1区医学

Ocular Surface Pub Date : 2024-08-08 DOI: 10.1016/j.jtos.2024.08.005

{"title":"The effects of age and dysfunction on meibomian gland population dynamics","authors":"","doi":"10.1016/j.jtos.2024.08.005","DOIUrl":"10.1016/j.jtos.2024.08.005","url":null,"abstract":"<div><h3>Purpose</h3><p>While meibomian gland dysfunction (MGD) is widely recognized as a major cause of evaporative dry eye disease, little is known about normal gland differentiation and lipid synthesis or the mechanism underlying gland atrophy and abnormal lipid secretion. The purpose of this study was to use single-cell and spatial transcriptomics to probe changes in cell composition, differentiation, and gene expression associated with two murine models of MGD: age-related gland atrophy in wild-type mice and altered meibum quality in acyl-CoA wax alcohol acyltransferase 2 (<em>Awat2</em>) knockout (KO) mice. Methods: Young (6 month) and old (22 month) wild type, C57Bl/6 mice and young (3 month) and old (13 month) Awat2 KO mice were used in these studies. For single-cell analysis, the tarsal plate was dissected from the upper and lower eyelids, and single cells isolated and submitted to the UCI Genomic Core, while for the spatial analysis frozen tissue sections were shipped to Resolve Biosciences on dry ice and sections probed in duplicate using a meibomian gland specific, 100 gene Molecular Chartography panel.</p></div><div><h3>Results</h3><p>Analysis of gene expression patterns identified the stratified expression of lipogenic genes during meibocyte differentiation, which may control the progressive synthesis of meibum lipids; an age-related decrease in meibocytes; and increased immune cell infiltration. Additionally, we detected unique immune cell populations in the <em>Awat2</em> KO mouse suggesting activation of psoriasis-like, inflammatory pathways perhaps caused by ductal dilation and hyperplasia.</p></div><div><h3>Conclusion</h3><p>Together these findings support novel mechanism controlling gland function and dysfunction.</p></div>","PeriodicalId":54691,"journal":{"name":"Ocular Surface","volume":null,"pages":null},"PeriodicalIF":5.9,"publicationDate":"2024-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141914997","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Development and validation of a method to generate phenol red thread tests 开发和验证生成酚红线测试的方法。

IF 5.9 1区医学

Ocular Surface Pub Date : 2024-08-08 DOI: 10.1016/j.jtos.2024.08.007

{"title":"Development and validation of a method to generate phenol red thread tests","authors":"","doi":"10.1016/j.jtos.2024.08.007","DOIUrl":"10.1016/j.jtos.2024.08.007","url":null,"abstract":"<div><h3>Purpose</h3><p>The aim of this study was to develop and validate a method to generate phenol red thread tests (PRTT) due to the lack of availability of commercial PRTT.</p></div><div><h3>Methods</h3><p>White cotton thread was dyed with phenol red (pH indicator) for 48 h, dried, cut, and sterilized. To validate its wicking ability, the thread was inserted into solutions of varying pH, flanking the pH of healthy tears, for different time intervals. To assess its diagnostic utility, PRTTs were performed <em>in vivo</em> on wildtype and a murine model of evaporative dry eye, <em>acyl-coA: wax alcohol acyltransferase 2</em> knockout (<em>Awat2</em> KO) mice.</p></div><div><h3>Results</h3><p>Two batches of PRTT were produced that had a similar appearance and function to the commercial product. <em>In vitro</em> testing revealed no significant differences in the wicking kinetics at any time point across the pH solutions for batch 1 and only one difference for batch 2 (pH 7.4 vs 7.8 at 5 s, <em>P</em> = 0.029). When comparing both batches, similar wicking kinetics were found with only two significant differences identified (pH 7.6 at 40 s and pH 7.8 at 35 s, <em>P</em> < 0.01). <em>In vivo</em>, our PRTT yielded similar measurements to the commercial PRTT in wildtype and <em>Awat2</em> KO mice and detected a significant increase in aqueous tear volume in the <em>Awat2</em> KO mice (commercial: <em>P</em> = 0.015, our PRTT: <em>P</em> = 0.002).</p></div><div><h3>Conclusion</h3><p>Our method provides a reproducible diagnostic test that performs similarly to its commercial counterpart in a relevant dry eye model indicating that it can serve as a valid and reliable replacement.</p></div>","PeriodicalId":54691,"journal":{"name":"Ocular Surface","volume":null,"pages":null},"PeriodicalIF":5.9,"publicationDate":"2024-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141914993","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Topical anti-glaucoma medications effects on meibomian glands: Systematic review and meta-analysis 局部抗青光眼药物对睑板腺的影响：系统回顾和荟萃分析。

IF 5.9 1区医学

Ocular Surface Pub Date : 2024-08-05 DOI: 10.1016/j.jtos.2024.07.011

引用次数: 0

Evolution of therapeutic strategy based on oxidant-antioxidant balance for fuchs endothelial corneal dystrophy 基于氧化剂-抗氧化剂平衡的福氏内皮角膜营养不良症治疗策略的演变。

IF 5.9 1区医学

Ocular Surface Pub Date : 2024-08-05 DOI: 10.1016/j.jtos.2024.08.003

{"title":"Evolution of therapeutic strategy based on oxidant-antioxidant balance for fuchs endothelial corneal dystrophy","authors":"","doi":"10.1016/j.jtos.2024.08.003","DOIUrl":"10.1016/j.jtos.2024.08.003","url":null,"abstract":"<div><p>Fuchs endothelial corneal dystrophy (FECD) stands as the most prevalent primary corneal endothelial dystrophy worldwide, posing a significant risk to corneal homeostasis and clarity. Corneal endothelial cells exhibit susceptibility to oxidative stress, suggesting a nuanced relationship between oxidant-antioxidant imbalance and FECD pathogenesis, irrespective of FECD genotype. Given the constrained availability of corneal transplants, exploration into non-surgical interventions becomes crucial. This encompasses traditional antioxidants, small molecule compounds, biologics, and diverse non-drug therapies, such as gene-related therapy, hydrogen therapy and near infrared light therapy. This review concentrates on elucidating the mechanisms behind oxidant-antioxidant imbalance and the evolution of strategies to restore oxidant-antioxidant balance in FECD. It provides a comprehensive overview of both conventional and emerging therapeutic approaches, offering valuable insights for the advancement of non-surgical treatment modalities. The findings herein might establish a robust foundation for future research and the therapeutic strategy of FECD.</p></div>","PeriodicalId":54691,"journal":{"name":"Ocular Surface","volume":null,"pages":null},"PeriodicalIF":5.9,"publicationDate":"2024-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1542012424000831/pdfft?md5=ae3a6b427ff8c26380bedff5a04f79e8&pid=1-s2.0-S1542012424000831-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141904113","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Preservatives and ocular surface disease: A review 防腐剂与眼表疾病：综述。

IF 5.9 1区医学

Ocular Surface Pub Date : 2024-08-03 DOI: 10.1016/j.jtos.2024.08.001

{"title":"Preservatives and ocular surface disease: A review","authors":"","doi":"10.1016/j.jtos.2024.08.001","DOIUrl":"10.1016/j.jtos.2024.08.001","url":null,"abstract":"<div><p>Ocular surface disease (OSD) is a complex condition that can cause a range of symptoms (e.g, dryness, irritation, and pain) and can significantly impact the quality of life of affected individuals. Iatrogenic OSD, a common finding in patients with glaucoma who receive chronic therapy with topical ocular antihypertensive drugs containing preservatives such as benzalkonium chloride (BAK), has been linked to damage to the ocular surface barrier, corneal epithelial cells, nerves, conjunctival goblet cells, and trabecular meshwork. Chronic BAK exposure activates inflammatory pathways and worsens symptoms, compromising the success of subsequent filtration surgery in an exposure-dependent manner.</p><p>In eyes being treated for glaucoma, symptomatic treatment of OSD may provide some relief, but addressing the root cause of the OSD often necessitates reducing or, ideally, eliminating BAK toxicity. Strategies to decrease BAK exposure in patients with glaucoma encompass the use of preservative-free formulations or drugs with alternative and less toxic preservatives such as SofZia®, Polyquad, potassium sorbate, or Purite®. Though the benefits of these alternative preservatives are largely unproven, they might be considered when financial constraints prevent the use of preservative-free versions. For patients receiving multiple topical preserved drugs, the best practice is to switch to nonpreserved equivalents wherever feasible, regardless of OSD severity. Furthermore, nonpharmacological approaches, including laser or incisional procedures, should be considered.</p><p>This review explores the effects of BAK on the ocular surface and reviews strategies for minimizing or eliminating BAK exposure in patients with glaucoma in order to significantly improve their quality of life and prevent complications associated with chronic exposure to BAK.</p></div>","PeriodicalId":54691,"journal":{"name":"Ocular Surface","volume":null,"pages":null},"PeriodicalIF":5.9,"publicationDate":"2024-08-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141891417","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Unraveling the complexity – Insights and interventions of refractory vernal keratoconjunctivitis 揭开复杂的面纱--对难治性疱性角结膜炎的见解和干预措施。

IF 5.9 1区医学

Ocular Surface Pub Date : 2024-08-03 DOI: 10.1016/j.jtos.2024.07.009

引用次数: 0